Asymmetric Binding to NS5A by Daclatasvir (BMS-790052) and Analogs Suggests Two Novel Modes of HCV Inhibition

[Image: see text] Symmetric, dimeric daclatasvir (BMS-790052) is the clinical lead for a class of picomolar inhibitors of HCV replication. While specific, resistance-bearing mutations at positions 31 and 93 of domain I strongly suggest the viral NS5A as target, structural mechanism(s) for the drugs’...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Med Chem
Main Authors: Nettles, James H., Stanton, Richard A., Broyde, Joshua, Amblard, Franck, Zhang, Hongwang, Zhou, Longhu, Shi, Junxing, McBrayer, Tamara R., Whitaker, Tony, Coats, Steven J., Kohler, James J., Schinazi, Raymond F.
Formato: Artigo
Idioma:Inglês
Publicado em: American Chemical Society 2014
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4266333/
https://ncbi.nlm.nih.gov/pubmed/25365735
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/jm501291c
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados